AVT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Avnet is not a clear buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has constructive analyst support and improving cycle signals, but the current technical setup is still weak and the latest price is sitting below key resistance with downside momentum still present. My direct view: hold for now, not a buy today.
AVT is in a short-term weak trend despite longer-cycle improvement in the business. Price is 82.15, essentially flat vs the previous close, but the technical picture is still bearish: MACD histogram is -1.014 and expanding negatively, showing downside momentum. RSI_6 at 27.35 is oversold-ish but not a clean reversal signal. Moving averages are converging, which suggests a possible base formation, but price is below pivot 87.652 and below resistance levels R1 92.339 and R2 95.235. Support is nearby at S1 82.965 and S2 80.069, so the stock is close to support but not yet showing a confirmed turn.
["Analyst upgrades and higher price targets across BofA, Raymond James, and Truist.", "BofA noted backlog extending, book-to-bill above 1 across regions, and lead-time extensions, which are constructive cycle indicators.", "Raymond James and Truist both pointed to continued recovery across regions and improving demand.", "Options flow is bullish, with low put-call ratios suggesting positive sentiment.", "Stock-trend model suggests upside over the next month, with a 9.95% chance-based move higher."]
["No news in the recent week, so there is no fresh catalyst to drive immediate upside.", "Technical momentum remains negative: MACD is below zero and worsening.", "Price is still below the pivot and key resistance levels, so the chart has not confirmed a breakout.", "Insider and hedge fund trading trends are neutral, offering no strong accumulation signal.", "No recent congress trading data or influential insider/politician buying to support conviction."]
No usable latest-quarter financial snapshot was provided because the financial data field returned an error. However, analyst commentary indicates the latest March quarter showed recovery across regions and end markets, with demand broadening, margin expansion, and guidance above consensus. The company appears to be in a cyclical upturn, but I cannot verify the exact quarter-season financials from the supplied dataset.
Analyst sentiment has clearly improved over the last few weeks. Truist upgraded AVT to Buy from Hold and raised its target to $80, then later to $95. Raymond James kept a Strong Buy and lifted its target to $95, citing recovery and margin expansion. BofA upgraded AVT to Neutral from Underperform and raised its target to $96, saying backlog, book-to-bill, and lead times look constructive. Wall Street pros are overall bullish on the recovery story, but the latest BofA move to Neutral shows the stock may be nearing fair value after the recent run.
